Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is one of the most common inherited enzymatic disorders worldwide, affecting over 400 million people. If undiagnosed, it can lead to severe hemolytic anemia triggered by infections, certain foods (like fava beans), or specific drugs.
Neo G6PD, our newborn screening kit, is a highly sensitive and reliable diagnostic solution designed for the early detection of G6PD deficiency in newborns. Developed in compliance with international quality standards (ISO 13485) and approved by Iran’s Food and Drug Administration, this kit enables clinical laboratories and screening centers to identify at-risk infants within the first days of life when timely intervention can prevent life-threatening complications.
Semi-qualitative method for measuring Glucose-6-Phosphate Dehydrogenase (G6PD) activity in blood samples. Using UV absorbance at 340 nm, this reliable and easy-to-use kit enables accurate detection of G6PD deficiency essential for preventing drug- or infection-induced hemolysis.
In 2014 (1393 in the Persian calendar), Misaq Talashgaran introduced the Neo-G6PD Kit, developed by its dedicated scientific team.
What sets the Neo-G6PD kit apart is its fully ready-to-use R1 and R2 reagents, eliminating the need for preparation or dilution. Additionally, it offers excellent reagent stability, ensuring consistent performance even under variable lab conditions.
These advantages make Neo-G6PD by Misaq Talashgaran the smart choice for Laboratory colleagues seeking fast, reliable, and worry-free results in G6PD deficiency screening.
